Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Injuries | 6 | 2014 | 55 | 1.070 |
Why?
|
| Swimming | 4 | 2009 | 22 | 0.910 |
Why?
|
| Smoke Inhalation Injury | 2 | 2023 | 3 | 0.840 |
Why?
|
| Burns | 2 | 2023 | 162 | 0.710 |
Why?
|
| Length of Stay | 2 | 2023 | 659 | 0.530 |
Why?
|
| Recovery of Function | 4 | 2014 | 200 | 0.490 |
Why?
|
| Spinal Cord | 3 | 2009 | 132 | 0.440 |
Why?
|
| Cellophane | 1 | 2013 | 1 | 0.420 |
Why?
|
| Dog Diseases | 1 | 2013 | 9 | 0.410 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2013 | 24 | 0.410 |
Why?
|
| Portal System | 1 | 2013 | 17 | 0.410 |
Why?
|
| Cat Diseases | 1 | 2012 | 7 | 0.400 |
Why?
|
| Adrenalectomy | 1 | 2012 | 31 | 0.390 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2012 | 49 | 0.380 |
Why?
|
| Vascular Malformations | 1 | 2013 | 103 | 0.360 |
Why?
|
| Adenoma | 1 | 2012 | 113 | 0.350 |
Why?
|
| Hindlimb | 2 | 2009 | 33 | 0.340 |
Why?
|
| Laparoscopy | 1 | 2012 | 180 | 0.340 |
Why?
|
| Exercise Therapy | 1 | 2009 | 100 | 0.290 |
Why?
|
| Acute Kidney Injury | 2 | 2023 | 315 | 0.270 |
Why?
|
| Trauma Severity Indices | 1 | 2006 | 51 | 0.260 |
Why?
|
| Tyramine | 1 | 2005 | 4 | 0.240 |
Why?
|
| Amyloid beta-Peptides | 1 | 2025 | 66 | 0.220 |
Why?
|
| Pericytes | 1 | 2023 | 13 | 0.220 |
Why?
|
| Peptides | 1 | 2005 | 229 | 0.220 |
Why?
|
| RNA | 1 | 2023 | 172 | 0.200 |
Why?
|
| Intensive Care Units | 1 | 2024 | 233 | 0.200 |
Why?
|
| Sexual Harassment | 1 | 2021 | 9 | 0.190 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2021 | 10 | 0.180 |
Why?
|
| Animals | 9 | 2023 | 13523 | 0.180 |
Why?
|
| Pharmaceutical Services | 1 | 2021 | 52 | 0.180 |
Why?
|
| Rats | 6 | 2014 | 3202 | 0.180 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 331 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 55 | 0.170 |
Why?
|
| Motor Activity | 2 | 2014 | 224 | 0.170 |
Why?
|
| Pharmacies | 1 | 2021 | 60 | 0.170 |
Why?
|
| Body Surface Area | 1 | 2019 | 27 | 0.160 |
Why?
|
| Bilirubin | 1 | 2019 | 43 | 0.160 |
Why?
|
| Creatinine | 1 | 2019 | 149 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 38 | 0.150 |
Why?
|
| Anemia | 1 | 2019 | 74 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 93 | 0.150 |
Why?
|
| Vasoconstrictor Agents | 1 | 2019 | 81 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 590 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 155 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2009 | 1552 | 0.140 |
Why?
|
| Heart Failure | 1 | 2023 | 571 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 3391 | 0.120 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 38 | 0.110 |
Why?
|
| Middle Aged | 4 | 2025 | 13014 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6578 | 0.110 |
Why?
|
| Female | 7 | 2025 | 28105 | 0.110 |
Why?
|
| Osmotic Fragility | 1 | 2013 | 1 | 0.100 |
Why?
|
| Mechanics | 1 | 2013 | 1 | 0.100 |
Why?
|
| Sterilization | 1 | 2013 | 9 | 0.100 |
Why?
|
| Tensile Strength | 1 | 2013 | 31 | 0.100 |
Why?
|
| Surface Properties | 1 | 2013 | 62 | 0.100 |
Why?
|
| Dogs | 1 | 2013 | 183 | 0.100 |
Why?
|
| Cats | 1 | 2012 | 73 | 0.100 |
Why?
|
| Male | 5 | 2025 | 26696 | 0.100 |
Why?
|
| Adolescent | 2 | 2021 | 6692 | 0.090 |
Why?
|
| Humans | 8 | 2025 | 52336 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 3872 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5407 | 0.080 |
Why?
|
| Aged | 2 | 2025 | 10109 | 0.080 |
Why?
|
| Permeability | 1 | 2009 | 67 | 0.080 |
Why?
|
| Thoracic Vertebrae | 1 | 2009 | 37 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 4319 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2009 | 333 | 0.080 |
Why?
|
| External Fixators | 1 | 2008 | 10 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2008 | 91 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 555 | 0.070 |
Why?
|
| Spine | 1 | 2008 | 88 | 0.070 |
Why?
|
| Adult | 2 | 2021 | 14139 | 0.070 |
Why?
|
| Biofeedback, Psychology | 1 | 2006 | 18 | 0.060 |
Why?
|
| Brain | 2 | 2025 | 1323 | 0.060 |
Why?
|
| Locomotion | 1 | 2006 | 85 | 0.060 |
Why?
|
| Walking | 1 | 2006 | 104 | 0.060 |
Why?
|
| Deferoxamine | 1 | 2005 | 9 | 0.060 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2005 | 9 | 0.060 |
Why?
|
| Iron Chelating Agents | 1 | 2005 | 12 | 0.060 |
Why?
|
| Monoamine Oxidase | 1 | 2005 | 15 | 0.060 |
Why?
|
| Catalase | 1 | 2005 | 74 | 0.060 |
Why?
|
| Huntington Disease | 1 | 2005 | 23 | 0.060 |
Why?
|
| tau Proteins | 1 | 2025 | 26 | 0.060 |
Why?
|
| Blood-Brain Barrier | 1 | 2025 | 49 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 167 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2005 | 120 | 0.060 |
Why?
|
| Transfection | 1 | 2005 | 372 | 0.060 |
Why?
|
| Dopamine | 1 | 2005 | 172 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2025 | 203 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2023 | 19 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2024 | 149 | 0.050 |
Why?
|
| Pain Management | 1 | 2024 | 178 | 0.050 |
Why?
|
| Cell Line | 1 | 2005 | 1045 | 0.050 |
Why?
|
| Critical Care | 1 | 2024 | 216 | 0.050 |
Why?
|
| Neurons | 1 | 2005 | 418 | 0.050 |
Why?
|
| DNA | 1 | 2005 | 550 | 0.050 |
Why?
|
| Gender Identity | 1 | 2021 | 26 | 0.050 |
Why?
|
| Atracurium | 1 | 2021 | 5 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 289 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2023 | 985 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2024 | 2428 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 1532 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 1484 | 0.030 |
Why?
|
| Nerve Growth Factor | 1 | 2014 | 12 | 0.030 |
Why?
|
| Urination | 1 | 2014 | 20 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 28 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 28 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 101 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2014 | 41 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2014 | 194 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 127 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 186 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 5965 | 0.030 |
Why?
|
| Electronics, Medical | 1 | 2008 | 4 | 0.020 |
Why?
|
| Evoked Potentials, Motor | 1 | 2008 | 9 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2008 | 11 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2008 | 34 | 0.020 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2008 | 72 | 0.020 |
Why?
|